ECSP23081880A - PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND ITS USE - Google Patents

PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND ITS USE

Info

Publication number
ECSP23081880A
ECSP23081880A ECSENADI202381880A ECDI202381880A ECSP23081880A EC SP23081880 A ECSP23081880 A EC SP23081880A EC SENADI202381880 A ECSENADI202381880 A EC SENADI202381880A EC DI202381880 A ECDI202381880 A EC DI202381880A EC SP23081880 A ECSP23081880 A EC SP23081880A
Authority
EC
Ecuador
Prior art keywords
compositions
pembrolizumab
pharmaceutical composition
infectious diseases
malignant neoplasms
Prior art date
Application number
ECSENADI202381880A
Other languages
Spanish (es)
Inventor
Aleksandr Olegovich Iakovlev
Anastasiia Alekseevna Andreeva
Ekaterina Aleksandrovna Lomkova
Alina Aleksandrovna Kostandian
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021112111A external-priority patent/RU2791857C2/en
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of ECSP23081880A publication Critical patent/ECSP23081880A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere al campo de la farmacia y la medicina, específicamente a las composiciones farmacéuticas del anticuerpo anti-PD-1 pembrolizumab, que pueden ser composiciones acuosas o liofilizadas. La invención se refiere además al uso de dichas composiciones para el tratamiento de neoplasias malignas o enfermedades infecciosas, así como al uso de dichas composiciones para producir un medicamento destinado a tratar neoplasias malignas o enfermedades infecciosas.The invention relates to the field of pharmacy and medicine, specifically to the pharmaceutical compositions of the anti-PD-1 antibody pembrolizumab, which can be aqueous or lyophilized compositions. The invention further relates to the use of said compositions for the treatment of malignant neoplasms or infectious diseases, as well as to the use of said compositions to produce a medicament intended to treat malignant neoplasms or infectious diseases.

ECSENADI202381880A 2021-04-27 2023-10-25 PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND ITS USE ECSP23081880A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021112111A RU2791857C2 (en) 2021-04-27 Pharmaceutical composition of pembrolizumab and use thereof

Publications (1)

Publication Number Publication Date
ECSP23081880A true ECSP23081880A (en) 2023-11-30

Family

ID=83848424

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202381880A ECSP23081880A (en) 2021-04-27 2023-10-25 PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND ITS USE

Country Status (9)

Country Link
EP (1) EP4329729A1 (en)
CN (1) CN117835965A (en)
AR (1) AR125470A1 (en)
CO (1) CO2023014166A2 (en)
CR (1) CR20230527A (en)
EC (1) ECSP23081880A (en)
MA (1) MA62939A1 (en)
TW (1) TW202308692A (en)
WO (1) WO2022231481A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050894T2 (en) * 2015-04-17 2021-01-28 Bristol Myers Squibb Co Compositions comprising a combination of ipilimumab and nivolumab
US11608357B2 (en) * 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
CA3063324A1 (en) * 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP3876978A4 (en) * 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Also Published As

Publication number Publication date
CO2023014166A2 (en) 2024-02-05
CN117835965A (en) 2024-04-05
MA62939A1 (en) 2024-02-29
AR125470A1 (en) 2023-07-19
TW202308692A (en) 2023-03-01
EP4329729A1 (en) 2024-03-06
CR20230527A (en) 2024-02-13
WO2022231481A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
ECSP20020410A (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THE SAME
PE20191474A1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CL2018000223A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
UY37741A (en) INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRUS REPLICATION
ECSP19070369A (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
ECSP18073293A (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
ECSP18073366A (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
NI201900098A (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
NI201900119A (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
UY38228A (en) TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CU20140037A7 (en) DERIVATIVES OF ESTRA- 1,3,5 (10), 16- TETRAEN- 3- CARBOXIMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
UY37729A (en) NEW COMPOUNDS THAT INHIBIT THE ACTIVITY OF Nav1.7
ECSP20020949A (en) ANTI-EGFR DRUG-ANTIBODY CONJUGATES (ADC) AND THEIR USES
CL2019002480A1 (en) Pyrazole derivatives as bromodomain inhibitors.
MX2020004513A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
CL2022003426A1 (en) Levilimab Aqueous Pharmaceutical Composition and Its Use
ECSP22021881A (en) AQUEOUS PHARMACEUTICAL COMPOSITION OF PROLGOLIMAB ANTI-PD1 ANTIBODY AND ITS USE
ECSP23081880A (en) PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND ITS USE
CL2019002020A1 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's disease.
BR112019017314A2 (en) pharmaceutical compositions for combination therapy
CO2021002980A2 (en) Dendrimer formulations
BR112016026814A8 (en) 2,2,2-trifluoroethyl-thiadiazines, intermediate, its use and preparation process, and pharmaceutical composition
BR112023022647A2 (en) 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, METHOD OF PREPARATION THEREOF AND MEDICAL USE THEREOF
PL425356A1 (en) Application of α,β dihydro xanthohumol